A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis

PLoS Computational Biology

Volumn 10, Issue 8, 2014, Pages

  Conway, Jessica M ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY (ORGANIC); PATIENT TREATMENT; VIRUSES;

DRUG CONCENTRATION; EFFECTIVENESS MODELS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION MODELS; REALISTIC MODEL; SIMPLE MODELING; TIME VARYING; VIRAL DISEASE; VIRUS INFECTION;

DISEASE CONTROL;

ALPHA INTERFERON; DANOPREVIR; MERICITABINE; PEGINTERFERON; RIBAVIRIN; SILIBININ; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS C; COMPENSATED LIVER CIRRHOSIS; CONSTANT EFFECTIVENESS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C VIRUS; HUMAN; LIVER CELL; STEADY STATE; TIME VARYING EFFECTIVENESS; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; VIROLOGY;

ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; HEPACIVIRUS; HEPATITIS C; HUMANS; MODELS, BIOLOGICAL; VIRAL LOAD;

EID: 84936790642     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003769     Document Type: Article

References (39)

1. Schneider M, Sarrazin C, (2014) Antiviral therapy of hepatitis C in 2014: Do we need resistance testing? Antiviral Res 105: 64–71.
2. Pawlotsky J, (2013) Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 369: 321–342.
3. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282: 103–107.
4. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS, (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922–4.
5. Guedj J, Neumann AU, (2010) Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 267: 330–40.
6. Guedj J, Perelson AS, (2011) Second-phase hepatitis C virus RNA decline during telapravir-based therapy increases with drug effectiveness: implications for treatment initiation. Hepatology 53: 1801–1808.
7. Rong L, Dahari H, Ribeiro RM, Perelson AS, (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.
8. Shudo E, Ribeiro RM, Perelson AS, (2008) Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat 15: 357–62.
9. Shudo E, Ribeiro RM, Perelson AS, (2008) Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b. J Viral Hepat 15: 379–82.
10. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson E, et al. (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87: 706–713.
11. Shudo E, Ribeiro RM, Talal AH, Perelson AS, (2008) A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther 13: 919–26.
12. Shudo E, Ribeiro RM, Perelson AS, (2009) Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Met 5: 321–32.
13. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, et al. (2003) Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 23 Suppl 113–8.
14. Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, et al. (2006) Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 43: 943–53.
15. Burnham KP, Anderson DR (2002) Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York: Springer, 2nd edition.
16. Guedj J, Dahari H, Shudo E, Smith P, Perelson AS, (2012) Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55: 1030–1037.
17. Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, et al. (2014) Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 19: 211–220.
18. Ma H, WR J, Robledo N, Leveque V, Ali S, et al. (2007) Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 282: 29812–29820.
19. Canini L, DebRoy S, Mariño, Conway JM, Crespo G, et al. (2014) Severity of liver disease affects hepatitis C virus kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther: In press.
20. Dahari H, Guedj J, Perelson AS, (2011) Silibinin's mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology 54: 749.
21. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS, (2012) Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 56: 1019–24.
22. Magnus W, (1954) On the exponential solution of differential equations for a linear operator. Commun Pur Appl Math VII: 649–673.
23. Blanes S, Casas F, Oteo J, Ros J, (2009) The Magnus expansion and some of its applications. Physical Reports 470: 151–238.
24. Spanier J, Oldham KB (1987) An Atlas of Functions. USA: Hemisphere Publishing Corporation.
25. Rong L, Guedj J, Dahari H, Coffield DJ, JrLevi M, et al. (2013) Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comp Biol 9: e1002959.
26. Guedj J, Dahari H, Rong L, Sansone N, Nettles R, et al. (2013) Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA 110: 3991–3996.
27. Edwards CH, Penney DE (1998) Calculus with Analytic Geometry. 5th edition. USA: Prentice-Hall Inc.
28. Blaising J, Lévy P, Gondeau C, Phelip C, Varbanov M, et al. (2013) Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 15: 1866–1882.
29. Perelson AS, Nelson P, (1999) Mathematical analysis of HIV-1: Dynamics in vivo. SIAM Rev 41: 3–44.
30. Perelson AS, (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 5: 28–36.
31. Tsiang M, F RJ, Toole JJ, Gibbs CS, (1999) Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29: 1863–1869.
32. Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, et al. (2001) Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34: 1012–1020.
33. Dahari H, Shudo E, Ribeiro RM, Perelson AS, (2009) Modeling complex decay profiles of hepatitis B virus. Hepatology 49: 32–38.
34. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of influenza A virus infection in humans. J Virol 80: 7590–7599.
35. Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, et al. (2008) Modeling amantadine treatment of influenza A in vitro. J Theor Biol 254: 439–451.
36. Dahari H, Affoso de Araujo ES, L HB, Layden TJ, Cotler SJ, et al. (2010) Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes. J Hepatol 53: 460–467.
37. Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, et al. (2011) Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS 25: 1179–1187.
38. Dixit NM, Perelson AS, (2004) Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokineticsand intracellular delay. J Theor Biol 226: 95–109.
39. Goldschmidt V, Marquet R, (2004) Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors. Int J Biochem Cell Biol 36: 1687–1705.